1stOncology™: Cancer Intelligence Service – Page 6837 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

On October 3, 2022 Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate (ADC)-based therapies, reported that global oncology leader, Genmab has licensed a novel antibody related to one of OBT’s IO programs (Press release, Oxford BioTherapeutics, OCT 3, 2022, View Source [SID1234621655]). The target was discovered using Oxford BioTherapeutics’ proprietary OGAP drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody. In addition to the upfront payment, OBT will receive additional development and regulatory milestone payments as well as royalties on any future product sales. This represents the first major license agreement for OBT’s IO programs to a world leader in the field of antibody-based oncology medicines.

"We are pleased to license one of our leading immuno-oncology assets to a world leading biotechnology company like Genmab, who have a wealth of internationally renowned expertise in the fields of antibody development and oncology," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. "This licensing deal enables OBT to add further depth and momentum into its drug pipeline by having this innovative asset developed by a partner."

TC BioPharm to Present at Upcoming Investor Conferences

On October 3, 2022 TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, reported that management will be presenting at the Dawson James 7th Annual Small Cap Growth Conference and LD MICRO Main Event XV (Press release, TC Biopharm, OCT 3, 2022, View Source [SID1234621654]).

TC BioPharm management will host one-on-one meetings with institutional investors at these conferences. Meetings can be scheduled through the firm hosting each event or by contacting TC BioPharm directly at [email protected]

Upcoming Conferences

The Dawson James 7th Annual Small Cap Growth Conference

LD MICRO Main Event XV

AIkido Pharma Continues Share Repurchase Program

On October 3, 2022 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company’s Board of Directors on January 21, 2022 (Press release, AIkido Pharma, OCT 3, 2022, View Source [SID1234621653]).

The Company reported that on September 30, 2022, the Company purchased 41,096 shares of common stock at $ 7.1034 per share.

Anthony Hayes, CEO of Aikido stated, "The Company’s stock price is still below our book value, so we are continuing to allocate capital under our repurchase plan. The board believes in the Company and our plans moving forward."

Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b -18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, including blackout period restrictions.

Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market

On October 3, 2022 Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, reported that the Company has submitted the AMNOG dossier to "The Federal Joint Committee" (G-BA) in Germany (Press release, Oncopeptides, OCT 3, 2022, View Source;germany-first-market-301639005.html [SID1234621651]). This initiates the commercial launch of Pepaxti (melphalan flufenamide) and thus Germany will be the first market in Europe where the drug is launched.

On August 18, the European Commission granted Pepaxti, in combination with dexamethasone, Marketing Authorization in the European Union and countries in the European Economic Area, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

"The launch of Pepaxti in Germany is an important milestone for Oncopeptides and very good news for patients with triple class refractory disease," says Jakob Lindberg, CEO of Oncopeptides. "Multiple myeloma is an incurable disease, and despite the recent introduction of several novel therapies, there is a high unmet medical need that Pepaxti may satisfy, in particular in the large population of elderly patients with relapsed refractory multiple myeloma."

Oncopeptides will launch Pepaxti with a focused and lean organization, dedicated to providing patient access for the drug in Germany and Austria. The ex-manufacturer price amounts to 5.450 € per vial, concluding an average price of 10.900 € per cycle/month. The price reflects the clinical benefit for patients in the approved indication. The price is valid for one year and will be subject to negotiations with the National Association of Statutory Health Insurance Funds to set a reimbursed price for German sick funds.

According to data from more than 60 sick funds in Germany in 2020, the prevalence of multiple myeloma is estimated to 59.000 patients and the annual incidence of diagnosed patients is approximately 9.200 cases. The indicated population for Pepaxti in Germany amounts to around 2.500 patients.

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

On October 3, 2022 Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D., "Pantherna") reported that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation)* (Press release, Astellas Pharma, OCT 3, 2022, View Source [SID1234621650]).

This agreement expands the scope of the technology evaluation agreement for research, which Astellas and Pantherna entered into in 2021, to include new target organ.

Pantherna owns a proprietary platform of state-of-the-art, unique mRNA molecules (PTXmRNAs) for enhancing the efficiency of mRNA actions in the body. Under the new agreement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programs for new target organ using a direct reprogramming approach. Astellas will be responsible for providing drug discovery ideas, preparing candidate compounds for technology evaluation, and performing research aimed at developing this therapeutic modality, while Pantherna will be responsible for providing technical information and development support.

"We are excited about this expansion of our collaboration with Astellas," said Pantherna’s Chief Executive Officer, Klaus Giese, Ph.D. "We feel honored that Astellas, as a leading pharmaceutical company, has underscored their interest in leveraging the unique aspects of our proprietary therapeutic mRNA technology."

"Through this agreement, which expands the scope of our collaboration with Pantherna, we will create innovative regenerative medicine programs for new target organ, and we expect that we will be able to thereby expand the treatment options for diseases with high unmet medical needs." said Taiji Sawamoto, Ph.D., Executive Vice President, Applied Research & Operations, at Astellas. "The collaboration with Pantherna is an initiative which synergistically integrates Astellas’ expertise with mRNA as a therapeutic modality and its capabilities cultivated in the research field of direct reprogramming, and will promote the development of next-generation treatments using a new modality/technology based on the Focus Area approach strategy."

* Direct reprogramming: Direct conversion of the fate of cells without passing through the pluripotent state. View Source